title: [Interest of the cervical gland dissection after radiotherapy with or without chemotherapy].
abstract: OBJECTIVE
  The aim of this study was to evaluate the necessity and morbidity of neck dissection after radiation therapy within organ preservation treatment.
  
  
  METHODS
  We present a retrospective study of 64 patients, treated initially by radiotherapy with or without chemotherapy for squamous cell carcinoma of head and neck with cervical metastases (> 2 cm), who underwent post-radiation neck dissection between January 1992 and August 2000. Eight (13%) patients were classified T1, nineteen (30%) T2, twenty (31%) T3, eleven (17%) T4 and six (9%) Tx. Eleven patients had N1 neck disease (17%), fifteen patients N2a (24%), eleven patients N2b (17%) and twenty-seven patients N3 (42%).
  
  
  RESULTS
  Follow-up ranged from 3 to 86 months with a mean of 39 months. The average length of time between neck dissection and the end of treatment was 60 days. Complications were recorded in 21 patients (33%). Forty-four (68%) of 64 patients had microscopic residual disease. Eight (72%) of 11 patients with N1 neck disease and 17 (63%) of 27 patients with N3 neck disease had pathology. Initial N status was not a predictive factor of microscopic residual disease (p = 0.51). There was no significant relationship between clinical residual adenopathy and microscopic residual disease (p = 0.53). Fourteen patients are still alive without recurrent disease. Eight (57%) of these 14 patients had a positive pathology at the time of neck dissection. The mean follow-up time of these patients is 32.6 months, with a follow up longer than 2 years for half of them (n = 7).
  
  
  CONCLUSIONS
  Neck dissection after radiation was planned for all patients with an initial node > 2 cm in diameter regardless of clinical response in the neck. We confirm that neck dissection appears to be safe after radiotherapy and is necessary because it improves quality of life and prevents fatal evolution with uncontrollable neck disease.
authors.affiliation: CHU Pellegrin, service d'ORL et de chirurgie cervico-faciale, 33076 Bordeaux, France. thierry.houliat@chu-bordeaux.fr
authors.forename: Th
authors.initials: T
authors.lastname: Houliat
authors.forename: D
authors.initials: D
authors.lastname: N'Guyen
authors.forename: L
authors.initials: L
authors.lastname: Eimer
authors.forename: B
authors.initials: B
authors.lastname: Baltazart
authors.forename: C
authors.initials: C
authors.lastname: Convert
authors.forename: K
authors.initials: K
authors.lastname: Diallo
authors.forename: J
authors.initials: J
authors.lastname: Meynard
authors.forename: L
authors.initials: L
authors.lastname: Traissac
mesh_terms: D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D017783:Superior Cervical Ganglion